This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Ziresovir
- DrugBank Accession Number
- DB15145
- Background
Ziresovir is under investigation in clinical trial NCT03699202 (Anti-RSV Study in Chinese Patients (ASCENT)).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Ziresovir (DB15145)
- Weight
- Average: 439.53
Monoisotopic: 439.167810859 - Chemical Formula
- C22H25N5O3S
- Synonyms
- Ziresovir
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- XCF42D7AG4
- CAS number
- 1422500-60-4
- InChI Key
- GAAICKUTDBZCMT-UHFFFAOYSA-N
- InChI
- InChI=1S/C22H25N5O3S/c1-15-6-7-18-17(10-15)20(24-12-22(23)13-30-14-22)26-21(25-18)27-8-9-31(28,29)19-5-3-2-4-16(19)11-27/h2-7,10H,8-9,11-14,23H2,1H3,(H,24,25,26)
- IUPAC Name
- 4-(4-{[(3-aminooxetan-3-yl)methyl]amino}-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydro-1lambda6,4-benzothiazepine-1,1-dione
- SMILES
- CC1=CC2=C(NCC3(N)COC3)N=C(N=C2C=C1)N1CCS(=O)(=O)C2=CC=CC=C2C1
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Respiratory Syncytial Virus (RSV) Infection 1 2 Unknown Status Treatment Respiratory Syncytial Virus (RSV) Infection 1 1 Completed Health Services Research Healthy Subjects (HS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0868 mg/mL ALOGPS logP 1.41 ALOGPS logP 2.31 Chemaxon logS -3.7 ALOGPS pKa (Strongest Acidic) 15.52 Chemaxon pKa (Strongest Basic) 8.46 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 110.44 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 121.46 m3·mol-1 Chemaxon Polarizability 45.99 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at May 20, 2019 14:53 / Updated at February 21, 2021 18:55